Curated News
By: NewsRamp Editorial Staff
August 17, 2026
Dyadic Raises $2.9M in Registered Direct Offering
TLDR
- Dyadic's $2.9M raise funds scalable protein tech, potentially boosting market position.
- Dyadic's offering includes 3.625M shares at $0.795 and warrants at $0.84, closing Aug 14.
- Dyadic's non-animal proteins aim for sustainable, efficient products, benefiting global health and environment.
- Dyadic's C1 expression system enables rapid, cost-effective protein manufacturing, a biotech breakthrough.
Impact - Why it Matters
This news matters because it highlights a growing trend in biotech financing where companies like Dyadic are leveraging capital markets to fund innovation in sustainable protein production. For investors, it signals potential growth opportunities in the biotech sector, particularly in areas addressing global food security and environmental sustainability. The success of such offerings can influence market confidence and shape the future of non-animal protein platforms, which are critical for meeting the demands of a growing population while reducing environmental impact.
Summary
Dyadic International (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has announced a registered direct offering and concurrent private placement to raise approximately $2.9 million. The company entered into definitive agreements with an institutional investor to sell 3,625,000 common shares at $0.795 per share and warrants to purchase an equal number of shares at an exercise price of $0.84 per share, with the warrants priced at $0.005 each. The transactions are expected to close on or about Aug. 14, 2026, subject to customary conditions. Dyadic intends to use the net proceeds for working capital and general corporate purposes, alongside existing cash and investments. Aegis Capital Corp. is serving as the exclusive placement agent.
Dyadic is a global biotechnology company focused on developing scalable, non-animal protein production platforms for life sciences, food and nutrition, and bio-industrial markets. Its proprietary Dapibus™ and C1 expression systems enable rapid, cost-effective, and flexible manufacturing of high-value proteins. This capital raise will support the company's ongoing efforts to meet growing global demand for sustainable protein solutions.
MissionIR, a specialized communications platform, is disseminating this news as part of its services to enhance visibility for public companies. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, providing access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. This announcement reflects Dyadic's commitment to advancing its biotech innovations and underscores the role of strategic financing in driving growth in the biotechnology sector.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Dyadic Raises $2.9M in Registered Direct Offering
